0.70Open0.50Pre Close148 Volume1.32K Open Interest12.50Strike Price7.08KTurnover85.68%IV17.88%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier24DDays to Expiry0.42Extrinsic Value100Contract SizeAmericanOptions Type0.3195Delta0.1471Gamma24.36Leverage Ratio-0.0183Theta0.0020Rho7.78Eff Leverage0.0101Vega
Kura Oncology Stock Discussion
Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology | KURA Stock News
$Kura Oncology (KURA.US)$
No comment yet